OncoHost, Hengenix Biotech Exploring Lung Cancer Resistance Biomarkers in Immunotherapy Trial

Original source here.

NEW YORK – Hengenix Biotech, an affiliate of Shanghai Henlius Biotech, will use OncoHost’s Prophet platform to identify biomarkers in a Phase III trial testing Henlius’ anti-PD-1 antibody serplulimab plus chemotherapy in patients with extensive-stage small cell lung cancer (ES-SCLC).

OncoHost on Tuesday said that in the Phase III trial researchers will compare the activity of serplulimab plus chemotherapy against Roche’s anti-PD-1 antibody Tecentriq (atezolizumab) plus chemotherapy in previously untreated ES-SCLC patients. They will use the Prophet platform to look for proteomic biomarkers that characterize resistance patterns in patients with the goal of identifying those most likely to benefit from the serplulimab-chemotherapy combination.

Prophet analyzes 7,000 proteins in patients’ blood samples using the SomaLogic SomaScan platform and combines this with machine-learning models to select patients most likely to benefit from treatments. The platform can predict measures of efficacy such as overall survival and progression-free survival. Binyamina, Israel-based OncoHost licensed the SomaScan platform from SomaLogic in June 2022.

Earlier this year, Baylor Scott & White Research Institute in Texas and the Translational Genomics Research Institute at City of Hope similarly partnered with OncoHost to use the Prophet platform to research resistance mechanisms in non-small cell lung cancer.